Abstract
Various adenovirus (AdV) vector systems have proven to be lucrative options for gene delivery. They can serve as potential vaccine candidates for prevention of several common infectious diseases and hold the promise for gene therapy, especially for cancer. Several AdV vector-based therapies are currently at various stages of clinical trials worldwide, which make an immense interest of both the clinicians and researchers. Since these vectors are easy to manipulate, have broad tropism, and have the capability to yield high titers, this delivery system has a wide range of applications for different clinical settings. This chapter emphasizes on some of the current usages of AdV vectors and their production methods.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rowe WP, Huebner RJ, Gilmore LK et al (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84(3):570–573
Enders JF, Bell JA, Dingle JH et al (1956) Adenoviruses: group name proposed for new respiratory-tract viruses. Science 124(3212):119–120
Davison AJ, Benko M, Harrach B (2003) Genetic content and evolution of adenoviruses. J Gen Virol 84(Pt 11):2895–2908. https://doi.org/10.1099/vir.0.19497-0
Ewer KJ, Lambe T, Rollier CS et al (2016) Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol 41:47–54. https://doi.org/10.1016/j.coi.2016.05.014
Su C (2011) Adenovirus-based gene therapy for cancer. In: Xu K (ed) Viral gene therapy. InTech, Rijeka, p 06. https://doi.org/10.5772/19757
Pesonen S, Kangasniemi L, Hemminki A (2011) Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8(1):12–28. https://doi.org/10.1021/mp100219n
Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10(4):616–629. https://doi.org/10.1016/j.ymthe.2004.07.013
Vemula SV, Amen O, Katz JM et al (2013) Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res 178(2):398–403. https://doi.org/10.1016/j.virusres.2013.09.013
Sharma A, Tandon M, Bangari DS et al (2009) Adenoviral vector-based strategies for cancer therapy. Curr Drug ther 4(2):117–138
Raper SE, Chirmule N, Lee FS et al (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1–2):148–158
Harvey BG, Worgall S, Ely S et al (1999) Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Hum Gene Ther 10(17):2823–2837. https://doi.org/10.1089/10430349950016555
Zaiss AK, Machado HB, Herschman HR (2009) The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 108(4):778–790. https://doi.org/10.1002/jcb.22328
Pandey A, Singh N, Vemula SV et al (2012) Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 7(3):e33428. https://doi.org/10.1371/journal.pone.0033428
Mast TC, Kierstead L, Gupta SB et al (2010) International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28(4):950–957. https://doi.org/10.1016/j.vaccine.2009.10.145
Pratt WD, Wang D, Nichols DK et al (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17(4):572–581. https://doi.org/10.1128/cvi.00467-09
Wold WS, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421–433
Seregin SS, Amalfitano A (2010) Improving adenovirus based gene transfer: strategies to accomplish immune evasion. Viruses 2(9):2013–2036. https://doi.org/10.3390/v2092013
Kay MA, Meuse L, Gown AM et al (1997) Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 94(9):4686–4691
Engelhardt JF, Ye X, Doranz B et al (1994) Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 91(13):6196–6200
Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24(7):849–862. https://doi.org/10.1016/j.vaccine.2005.08.101
Mittal SK, Ahi YS, Vemula SV (2016) 19 - xenogenic adenoviral vectors A2 - curiel. In: David T (ed) Adenoviral vectors for gene therapy, 2nd edn. Academic Press, San Diego, pp 495–528. https://doi.org/10.1016/B978-0-12-800276-6.00019-X
Singh N, Pandey A, Jayashankar L et al (2008) Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 16(5):965–971. https://doi.org/10.1038/mt.2008.12
Moffatt S, Hays J, HogenEsch H et al (2000) Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 272(1):159–167. https://doi.org/10.1006/viro.2000.0350
Li X, Bangari DS, Sharma A et al (2009) Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392(2):162–168. https://doi.org/10.1016/j.virol.2009.06.029
Bangari DS, Sharma A, Mittal SK (2005) Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun 331(4):1478–1484. https://doi.org/10.1016/j.bbrc.2005.04.058
Ehrhardt A, Xu H, Kay MA (2003) Episomal Persistence of Recombinant Adenoviral Vector Genomes during the Cell Cycle In Vivo. J Virol 77(13):7689–7695. https://doi.org/10.1128/jvi.77.13.7689-7695.2003
Seiler MP, Cerullo V, Lee B (2007) Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 7(5):297–305
Gene Therapy Clinical Trials Worldwide (2017). Available from; http://www.abedia.com/wiley/vectors.php). http://www.abedia.com/wiley/vectors.php
Smaill F, Jeyanathan M, Smieja M et al (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5(205):205ra134. https://doi.org/10.1126/scitranslmed.3006843
Vemula SV, Mittal SK (2010) Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther 10(10):1469–1487. https://doi.org/10.1517/14712598.2010.519332
Ahi YS, Bangari DS, Mittal SK (2011) Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11(4):307–320
Zhu J, Huang X, Yang Y (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol 81(7):3170–3180. https://doi.org/10.1128/jvi.02192-06
Sharma A, Tandon M, Ahi YS et al (2010) Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther 17(5):634–642. https://doi.org/10.1038/gt.2010.1
Hassan AO, Amen O, Sayedahmed EE et al (2017) Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses. PLoS One 12(10):e0186244. https://doi.org/10.1371/journal.pone.0186244
Kim EH, Han GY, Nguyen H (2017) An adenovirus-vectored influenza vaccine induces durable cross-protective hemagglutinin stalk antibody responses in mice. Viruses 9(8):E234. https://doi.org/10.3390/v9080234
Kamlangdee A, Kingstad-Bakke B, Anderson TK et al (2014) Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol 88(22):13300–13309. https://doi.org/10.1128/jvi.01532-14
Hoelscher MA, Singh N, Garg S et al (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 197(8):1185–1188. https://doi.org/10.1086/529522
Cao W, Liepkalns JS, Hassan AO et al (2016) A highly immunogenic vaccine against A/H7N9 influenza virus. Vaccine 34(6):744–749. https://doi.org/10.1016/j.vaccine.2015.12.062
de Vries RD, Rimmelzwaan GF (2016) Viral vector-based influenza vaccines. Hum Vaccin Immunother 12(11):2881–2901. https://doi.org/10.1080/21645515.2016.1210729
Hoelscher MA, Garg S, Bangari DS et al (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367(9509):475–481. https://doi.org/10.1016/s0140-6736(06)68076-8
Van Kampen KR, Shi Z, Gao P et al (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8):1029–1036. https://doi.org/10.1016/j.vaccine.2004.07.043
Fuchs JD, Bart PA, Frahm N et al (2015) Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals. J AIDS Clin Res 6(5):461. https://doi.org/10.4172/2155-6113.1000461
Milligan ID, Gibani MM, Sewell R et al (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: a randomized clinical trial. JAMA 315(15):1610–1623. https://doi.org/10.1001/jama.2016.4218
O'Hara GA, Duncan CJ, Ewer KJ et al (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205(5):772–781. https://doi.org/10.1093/infdis/jir850
Osman M, Mistry A, Keding A et al (2017) A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis 11(5):e0005527. https://doi.org/10.1371/journal.pntd.0005527
Ledgerwood JE, DeZure AD, Stanley DA et al (2017) Chimpanzee adenovirus vector ebola vaccine. N Engl J Med 376(10):928–938. https://doi.org/10.1056/NEJMoa1410863
Tapia MD, Sow SO, Lyke KE et al (2016) Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16(1):31–42. https://doi.org/10.1016/s1473-3099(15)00362-x
Crosby CM, Matchett WE, Anguiano-Zarate SS et al (2017) Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses. J Virol 91(2):e00720. https://doi.org/10.1128/jvi.00720-16
Li Y, Pong RC, Bergelson JM et al (1999) Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59(2):325–330
Shen YH, Yang F, Wang H et al (2016) Arg-Gly-Asp (RGD)-modified E1A/E1B double mutant adenovirus enhances antitumor activity in prostate cancer cells in vitro and in mice. PLoS One 11(1):e0147173. https://doi.org/10.1371/journal.pone.0147173
Wang H, Li ZY, Liu Y et al (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17(1):96–104. https://doi.org/10.1038/nm.2270
Biedermann K, Vogelsang H, Becker I et al (2005) Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol 207(2):199–206. https://doi.org/10.1002/path.1821
Harada H, Iwatsuki K, Ohtsuka M et al (1996) Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm Venereol 76(6):417–420
Schmitt CJ, Franke WW, Goerdt S et al (2007) Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein. J Invest Dermatol 127(9):2191–2206. https://doi.org/10.1038/sj.jid.5700849
Lee SY, Park HR, Rhee J et al (2013) Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma. Oncol Res 20(9):419–425. https://doi.org/10.3727/096504013x13657689383139
Vera B, Martinez-Velez N, Xipell E et al (2016) Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. PLoS One 11(1):e0147211. https://doi.org/10.1371/journal.pone.0147211
Ranki T, Pesonen S, Hemminki A et al (2016) Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer 4:17. https://doi.org/10.1186/s40425-016-0121-5
Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7(20):1707–1714. https://doi.org/10.1038/sj.gt.3301301
Graham FL, Smiley J, Russell WC et al (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36(1):59–74. https://doi.org/10.1099/0022-1317-36-1-59
Kamen A, Henry O (2004) Development and optimization of an adenovirus production process. J Gene Med 6(Suppl 1):S184–S192. https://doi.org/10.1002/jgm.503
Fallaux FJ, Bout A, van der Velde I et al (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9(13):1909–1917. https://doi.org/10.1089/hum.1998.9.13-1909
Howe JA, Pelka P, Antelman D et al (2006) Matching complementing functions of transformed cells with stable expression of selected viral genes for production of E1-deleted adenovirus vectors. Virology 345(1):220–230. https://doi.org/10.1016/j.virol.2005.09.029
Wen S, Schneider DB, Driscoll RM et al (2000) Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler Thromb Vasc Biol 20(6):1452–1458
Mitani K, Graham FL, Caskey CT et al (1995) Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 92(9):3854–3858
Parks R, Evelegh C, Graham F (1999) Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6(9):1565–1573. https://doi.org/10.1038/sj.gt.3300995
Alba R, Bosch A, Chillon M (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12(Suppl 1):S18–S27. https://doi.org/10.1038/sj.gt.3302612
Parks R, Chen L, Anton M et al (1996) A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 93(24):13565–13570
Hardy S, Kitamura M, Harris-Stansil T et al (1997) Construction of adenovirus vectors through Cre-lox recombination. J Virol 71(3):1842–1849
Vetrini F, Ng P (2010) Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2(9):1886–1917. https://doi.org/10.3390/v2091886
Stow ND (1981) Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. J Virol 37(1):171–180
He TC, Zhou S, da Costa LT et al (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95(5):2509–2514
Chartier C, Degryse E, Gantzer M et al (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 70(7):4805–4810
Wu C, Lei X, Wang J et al (2011) Generation of a replication-deficient recombinant human adenovirus type 35 vector using bacteria-mediated homologous recombination. J Virol Methods 177(1):55–63. https://doi.org/10.1016/j.jviromet.2011.06.016
Luo J, Deng ZL, Luo X et al (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2(5):1236–1247. https://doi.org/10.1038/nprot.2007.135
Ng P, Parks RJ, Cummings DT et al (1999) A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum Gene Ther 10(16):2667–2672. https://doi.org/10.1089/10430349950016708
Chen L, Anton M, Graham FL (1996) Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 22(6):477–488
Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70(11):7498–7509
Maizel JV Jr, White DO, Scharff MD (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36(1):115–125
Rux JJ, Burnett RM (2007) Large-scale purification and crystallization of adenovirus hexon. In: Wold WSM, Tollefson AE (eds) Adenovirus methods and protocols, Ad proteins, RNA lifecycle, host interactions, and phylogenetics, vol 2. Humana Press, Totowa, NJ, pp 231–250. https://doi.org/10.1007/978-1-59745-277-9_17
Acknowledgments
This work was supported by the Public Health Service grant—AI059374 from the National Institute of Allergy and Infectious Diseases, and the Hatch and Animal Health funds.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sayedahmed, E.E., Kumari, R., Mittal, S.K. (2019). Current Use of Adenovirus Vectors and Their Production Methods. In: Manfredsson, F., Benskey, M. (eds) Viral Vectors for Gene Therapy. Methods in Molecular Biology, vol 1937. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9065-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9065-8_9
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9064-1
Online ISBN: 978-1-4939-9065-8
eBook Packages: Springer Protocols